![]() ![]() Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and UNITY undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. ![]() Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include market conditions and the satisfaction of closing conditions related to the public offering. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in UNITY’s business and other risks described in the UNITY’s filings with the SEC. The inclusion of forward-looking statements should not be regarded as a representation by UNITY that any of its plans will be achieved. These statements are based on UNITY’s current beliefs and expectations and include the UNITY’s statements regarding the completion of its offering. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. UNITY cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. 6105, or by email at Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022, by email at or Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020, by email at or by telephone at (212) 205-7600. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at Copies of the prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained from: SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. The public offering is being made pursuant to a registration statement on Form S-3 previously filed with the Securities and Exchange Commission (“SEC”), which became effective on May 6, 2022. Wedbush PacGrow is acting as lead manager for the offering. SVB Securities, Cantor and Mizuho Securities are acting as joint book-running managers for the offering. UNITY intends to use the net proceeds from the offering to fund the ongoing clinical development of UBX1325, including the BEHOLD and ENVISION studies, and other general corporate purposes, including working capital, operating expenses and capital expenditures. The offering is expected to close on August 22, 2022, subject to customary closing conditions. All of the securities are being offered by UNITY. The gross proceeds to UNITY from the offering are expected to be approximately $45.0 million, before underwriting discounts and commissions and offering costs. The warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years following the date of issuance. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the pricing of an upsized underwritten public offering of 64,285,714 shares of its common stock and accompanying warrants to purchase up to 64,285,714 shares of common stock at a combined public offering price of $0.70 per share and accompanying warrant. 17, 2022 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |